Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers.
Julika BordeCorinna ErnstBarbara WappenschmidtDieter NiederacherKonstantin Weber-LassalleGunnar SchmidtJan HaukeAnne S QuanteNana Weber-LassalleJudit HorváthEsther Pohl-RescignoNorbert ArnoldAndreas RumpAndrea GehrigJulia HentschelUlrike FaustVéronique DutrannoyAlfons MeindlMaria KuzyakovaShan Wang-GohrkeBernhard Heinrich Friedrich WeberChristian SutterAlexander E VolkOlga GiannakopoulouAndrew J LeeChristoph EngelMarjanka K SchmidtAntonis C AntoniouRita K SchmutzlerKaroline B KuchenbaeckerJulika BordePublished in: Journal of the National Cancer Institute (2022)
PRSs may be used to personalize risk-adapted preventive measures for women with CHEK2 mutations. Larger studies are required to assess the role of PRSs in mCBC predisposition.
Keyphrases